Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 26, 2024 Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
Post-Stroke Depression in Older Adults: An Overview
AbstractDetailed data on post-stroke depression (PSD) in older adults are limited in spite of the high vulnerability of this population to stroke. In fact, PSD prevalence in older adults ranges from 16.0 to 43.9%; however, timing and instruments of evaluation often differ significantly across all available studies. The etiology, genetic and inflammatory factors, as well as structural brain alterations, are claimed as part of a multifaceted mechanism of action in PSD onset. Thus, the aim of this narrative review was to further elaborate on the prevalence, etiology, diagnosis, consequences and treatment of PSD in older adult...
Source: Drugs and Aging - February 23, 2024 Category: Geriatrics Source Type: research
Fatal Escitalopram-Induced Leukocytoclastic Vasculitis Clinically Simulating Drug Reaction with Eosinophilia and Systemic Symptoms Syndrome: Digging Deeper into an Uncommon Presentation
Dermatitis. 2024 Feb 21. doi: 10.1089/derm.2023.0323. Online ahead of print.NO ABSTRACTPMID:38386589 | DOI:10.1089/derm.2023.0323 (Source: Dermatitis)
Source: Dermatitis - February 22, 2024 Category: Dermatology Authors: Bouraoui Ouni Khadija Mansour Maha Lahouel Malek Sassi Nesrine Ben-Sayed Badreddine Sriha Mohamed Denguezli Neila Fathallah Raoudha Slim Source Type: research
Pharmacological management of gambling disorder: an update of the literature
Expert Rev Neurother. 2024 Feb 15. doi: 10.1080/14737175.2024.2316833. Online ahead of print.ABSTRACTINTRODUCTION: Gambling disorder (GD) is a mental health condition characterized by persistent and problematic betting behavior. GD generates distress and impairment, and treatment options include psychological and pharmacological interventions.AREAS COVERED: This narrative review explores existing pharmacological treatments for GD. The following classes of medications were considered: opioid-receptor antagonists (e.g. naltrexone and nalmefene), serotonin reuptake inhibitors (e.g. fluvoxamine, paroxetine, sertraline, escital...
Source: Expert Review of Neurotherapeutics - February 15, 2024 Category: Neurology Authors: Gemma Mestre-Bach Marc N Potenza Source Type: research
